Lynparza Use In Pregnancy & Lactation

Olaparib should not be used during pregnancy due to the teratogenic and genotoxic potential of olaparib. No studies have been conducted in pregnant women (see Pharmacology: Toxicology: Preclinical safety data under Actions).
If a female patient or a female partner of a male patient receiving Lynparza becomes pregnant, she should be apprised of the potential hazard to the foetus or potential risk of loss of the pregnancy (see Precautions).
FC tablet: Female partners of male patients taking Lynparza should also avoid pregnancy.
Contraception and pregnancy testing: Women of childbearing potential must use effective contraception during therapy and for one month after receiving the last dose of Lynparza (see Precautions). A pregnancy test should be performed on all women of childbearing potential prior to treatment, and pregnancy tests should be performed at regular intervals during treatment and at one month after receiving the last dose.
FC tablet: It is not known whether olaparib or its metabolites are found in seminal fluid. Male patients must use a condom during therapy and for 3 months after receiving the last dose of Lynparza when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients must also use effective contraception if they are of childbearing potential (see Precautions). Male patients should not donate sperm during therapy and for 3 months after receiving the last dose of Lynparza.
Breast-feeding: There are no data on the use of Lynparza in breast-feeding women. The excretion of olaparib in milk has not been studied in animals or in breast-feeding mothers. A risk to the newborn breast-feeding child cannot be excluded. Breast-feeding mothers are advised not to breast-feed during treatment with Lynparza and for one month after receiving the last dose (see Precautions).